Company* (Country; Symbol) |
Product | Description | Indication | Status (Date) |
AUTOIMMUNE | ||||
Anacor Pharmaceuticals* | AN2728 | Topical anti-inflammatory product | Psoriasis | Phase II achieved its objective in of defining the optimal duration of therapy (2/19) |
Hutchison Media-Pharma Ltd. (UK) | HMPL-004 | An oral botanical product that acts on multiple inflammatory products | Crohn's disease | Completed patient enrollment in a 100-patient Phase II trial (2/17) |
Theravance Inc. (THRX) and GlaxoSmithKline plc (UK) | | Inhaled corticosteroid fluticasone furoate | Mild, moderate and severe asthma | Phase IIb data showed that once-daily FF produced statistically significant improvements in patients' lung function compared to placebo (2/4) |
CANCER | ||||
Allos Therapeutics Inc. (ALTH) | Pralatrexate | Novel antifolate | Peripheral T-cell lymphoma | Pivotal Phase II data showed an estimated median duration of response of 287 days, or 9.4 months, a secondary endpoint of the trial (2/4) |
Ascenta Therapeutics Inc.* | AT-101 | A pan-Bcl-2 inhibitor | Prostate cancer | Phase II data showed it can be safely administered in combination with docetaxel and prednisone (2/27) |
AVEO Pharmaceuticals Inc.* | AV-951 | VEGF inhibitor | Advanced renal cell carcinoma | Phase II data showed a 91.7% disease control rate and a 20.1% objective response rate in treated patients (2/25) |
Cougar Biotechnology Inc. (CGRB) | CB7630 | Abiraterone acetate | Prostate cancer | Phase II data showed 77% of patients experienced a decline in prostate-specific antigen levels of greater than 30%, 22% experienced a decline of 50% or more and 26% had a decline of more than 90% (2/27) |
Curis Inc. (CRIS) and Genentech Inc. (NYSE:DNA) | GDC-0449 | An orally-administered small- molecule Hedgehog Pathway inhibitor | Metastatic or locally advanced basal cell carcinoma | Treated the first patient in a pivotal Phase II trial (2/12) |
Endocyte Inc.* | EC145 | A folate-targeted cyto-toxic drug | Platinum-resistant ovarian cancer | Started a Phase II trial (2/19) |
Peregrine Pharmaceuticals Inc. (PPHM) | Bavituximab | Monoclonal antibody that binds to phosphatidylserine | Non-small-cell lung cancer; breast cancer | Met its tumor response endpoint when used with chemotherapy in a Phase II trial in NSCLC (2/4); half of study patients achieved tumor response after two treatment cycles in a Phase II breast cancer study (2/11) |
Poniard Pharmaceuticals Inc. (PARD) | Picoplatin | Platinum chemotherapy agent | Metastatic castration-resistant prostate cancer | Phase II data of picoplatin in combination with docetaxel and prednisone showed it is active as a first-line therapy (2/25) |
Seattle Genetics Inc. (SGEN) | SGN-33 | Lintuzumab | Acute myeloid leukemia | Completed patient enrollment in a Phase IIb trial (2/25) |
CARDIOVASCULAR | ||||
Aastrom Biosciences Inc. (ASTM) | CRCs | Cardiac repair cells | Heart failure | Suspended Phase II enrollment while FDA reviews an incident under which a patient developed a serious adverse event associated with anesthesia management (2/2) |
Alkermes Inc. (ALKS) | ALKS 27 | An inhaled formulation of trospium based on Alkermes' AIR pulmonary technology | Chronic obstructive pulmonary disease | Began a Phase IIa study (2/18) |
Arena Pharmaceuticals Inc. (ARNA) | | Niacin receptor agonist | Atherosclerosis | Began a Phase II trial (2/18) |
BioMarin Pharmaceutical Inc. (BMRN) | 6R-BH4 | Sapropterin dihydro-chloride | Symptomatic peripheral arterial disease | Phase II data showed no statistical significance between treatment and placebo groups (2/3) |
Ligand Pharmaceuticals Inc. (LGND) | PS433540 | First-in-class dual-acting receptor agonist that targets the angiotensin and endothelin receptors | Hypertension | Phase IIb data showed it was safe and well tolerated and demonstrated statistically significant greater reductions in blood pressure than placebo (2/2) |
Stem Cell Therapeutics Corp. (Canada; CDNX:SSS) | | Beta-human chorionic gonadotropin and erythropoietin | Acute ischemic stroke | Phase IIa data showed no safety concerns, and all 12 patients improved (2/19) |
ThromboGenics NV (Belgium; BR:THR) and BioInvent International AB (Sweden; SSE:BINV) | TB-402 | Long-acting antibody that targets part of Factor VIII | Deep vein thrombosis | Started a 300-patient, Phase II trial (2/23) |
CENTRAL NERVOUS SYSTEM | ||||
Corcept Therapeutics Inc. (CORT) | Corlux | Cortisol receptor antagonist | Psychotic depression | Secondary endpoint analysis showed that the addition of Corlux to Risperdal resulted in less abdominal fat, lower fasting insulin levels and lower tri-glyceride levels, all of which were statistically significant compared to Risperdal alone (2/23) |
ExonHit Therapeutics SA (France; Paris:ALEHT) | EHT 0202 | Stimulates the alpha-secretase pathway | Alzheimer's disease | Completed patient enrollment in a Phase IIa trial (2/26) |
Minster Pharmaceuticals plc (UK; LSE:MPM) | Tonabersat | A neuronal gap junction blocker | To prevent migraine | Failed in a Phase IIb trial (2/2) |
Rexahn Pharmaceuticals Inc. (AMEX:RNN) | Serdaxin | An oral, extended-release tablet | Major depressive disorder | Started a Phase IIa trial (2/2) |
DIABETES | ||||
Arete Therapeutics Inc.* | AR9281 | An orally administered soluble epoxide hydrolase inhibitor | Type II diabetes | Started a Phase IIa trial (2/10) |
ConjuChem Biotechnologies Inc. (Canada; TSX:CJB) | PC-DAC: Exendin-4 | GLP-1 agonist | Diabetes | Phase II data confirm that it significantly reduced HbA1c and weight compared to placebo (2/10) |
CPEX Pharmaceuticals Inc. (CPEX) | Nasulin | Intranasal insulin candidate | Type II diabetes | Started a Phase II trial (2/24) |
Transition Therapeutics Inc. (Canada; TTHI) | TT-223 | Gastrin analogue | Type II diabetes | Completed patient enrollment for a Phase II study (2/5) |
INFECTION | ||||
BioCryst Pharmaceuticals Inc. (BCRX) | Peramivir | A neuraminidase inhibitor | Influenza | Phase II data showed no statistically significant differences among two doses of once-daily peramivir and twice-daily oseltamivir (2/23) |
GeoVax Labs Inc. (OTC BB: GOVX) | | Two-component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara | HIV/AIDS | Began a Phase IIa trial (2/20) |
PharmAthene Inc. (AMEX:PIP) | SparVax | Second-generation recombinant protective anthrax vaccine candidate | Anthrax | Phase II data suggested that it may be a promising protective anthrax vaccine for civilian defense (2/24) |
Raptor Pharmaceuticals Corp. (OTC BB: RPTP) | Cysteamine | Cysteamine bitartrate | Nonalcoholic steatohepatitis | Completed patient enrollment in its Phase IIa trial (2/5) |
Romark Laboratories* | Nitazoxanide | First of a new class of broad-spectrum antiviral drugs known as thiazolides | Hepatitis C virus | Phase II data showed that 82% and 100% of treatment-naive patients experienced undetectable serumHCV RNA after 12 weeks when treated with low and high dosages of nitazoxanide in combination with peginterferon and ribavirin (2/17) |
MISCELLANEOUS | ||||
Amicus Therapeutics Inc. (FOLD) | AT2220 | 1-deoxynojirimycin HCl | Pompe disease | Company suspended further enrollment and the FDA issued a clinical hold when two patients experienced serious adverse events that were probably treatment-related (2/27) |
Capstone Therapeutics* | AZX100 | A synthetic 24 amino acid peptide | Dermal scarring | Began dosing in a Phase II trial (2/10) |
CyDex Pharmaceuticals Inc.* | Captisol-Enabled | Budesonide/Zelastine nasal spray | Seasonal allergic rhinitis | Completed a Phase II with 108 patients (2/3) |
ESBATech AG* (Switzerland) | ESBA105 | A single-chain antibody fragment directed against TNF-alpha | Acute anterior uveitis | Started a Phase IIa study (2/24) |
Genzyme Corp. (GENZ) | Genz-112638 | Oral therapy | Gaucher disease | Phase II data showed it met its primary endpoint (2/20) |
Notes: * Privately held. Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||